机构最新研判来了！事关创新药、AI等板块

Group 1: Core Views - The innovation drug sector is identified as a strong growth area with significant potential for returns, as evidenced by the performance of funds heavily invested in this sector [2][3][4] - The AI and computing sectors are also highlighted as areas of opportunity, with funds showing substantial growth in net value due to strategic investments in these technologies [5][6][9] Group 2: Innovation Drug Sector - In Q2, the Longcheng Pharmaceutical Industry Selected Mixed Fund A achieved a net value growth rate of 35.86%, significantly outperforming its benchmark [3] - The fund's top holdings include major pharmaceutical companies, and the manager anticipates continued growth driven by overseas licensing and domestic sales expansion [4] - The overall sentiment in the innovation drug sector is positive, with expectations of strong performance based on clinical data and commercialization efforts [4] Group 3: AI and Computing Sector - The Yongying Technology Selected Mixed Fund A reported a net value growth rate of 32.28% in Q2, indicating strong performance relative to its benchmark [6] - The fund's top holdings include key players in the cloud computing and AI sectors, reflecting a strategic focus on these areas [7] - The fund manager emphasizes the importance of AI applications and the expected growth in domestic computing capabilities, predicting significant advancements in the coming year [9] Group 4: North Exchange Market - The North Exchange sector has shown strong performance, with funds like the Tongtai Vision Mixed Fund achieving over 48% returns year-to-date [10] - The fund's Q2 net value growth rate was 17.00%, and it focuses on high-growth potential companies within the North Exchange [11] - The fund employs a quantitative multi-factor strategy to optimize its portfolio, aiming to capitalize on future market opportunities [11]